PMC:7696151 / 20678-22332 JSONTXT 3 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T147 0-81 Sentence denotes In contrast, HCQ seems to affect the improvement of CHIKV chronic phase diseases.
T148 82-222 Sentence denotes In a recent multicenter study, the efficacy of HCQ was evaluated in 39 patients with rheumatic manifestation related to CHIKV chronic phase.
T149 223-419 Sentence denotes In four subjects, the treatment was interrupted due to the onset of side effects such as nausea, stomatitis, rash, headache, while the evolution of CHIKV disease was evaluated in only 22 patients.
T150 420-605 Sentence denotes After three months of treatment, evidence of synovitis was disappeared in 10 of 20 subjects (50%) with swollen joins while complete remission was verified in five patients (19.2%) [27].
T151 606-752 Sentence denotes However, another study demonstrated that the effects of HCQ in combination with MXT and sulfasalazine were superior to those shown in monotherapy.
T152 753-962 Sentence denotes In particular, in a randomized controlled open-label study, the impact of HCQ in monotherapy or association with MTX and sulfasalazine was assessed in 72 patients with chronic persistent chikungunya arthritis.
T153 963-1141 Sentence denotes In this trial, 400 mg/day HCQ were administrated to 35 subjects, while a combination of 15 mg/day MTX, 1 g/day sulfasalazine, and 400 mg/day HCQ was administrated to 37 patients.
T154 1142-1268 Sentence denotes Either treatment lasted 24 weeks and for the first 6 weeks, both groups received an escalated dose of prednisone (7.5 mg/day).
T155 1269-1391 Sentence denotes At the end of the 24th week, only the combination of drugs improved disease activity and reduced disability and pain [28].
T156 1392-1654 Sentence denotes These results, following those obtained in a previous uncontrolled 16-week study, since a reduction in ACR score was shown after MTX (15–20 mg/weekly) and HCQ (400 mg/day) administration to CHIKV infected patients with persistent inflammatory polyarthritis [29].